Vape Holdings, Inc. (OTCMKTS:VAPE) management reported that they have worked meticulously to scale back businesses. For the purpose, they have been cutting down unnecessary expenses and will continue to follow the same plan in coming period. The objective is to be achieve an operational breakeven and gradually become profitable. They expect to avoid toxic financing and deploy profits to grow company responsibly.
The business model
Vape Holdings said that they have been refocusing on core operations, which is advancing innovative goods and distributing them to leading retailers. In the coming period, they intend to launch “advanced ceramic” product line, named ONYX. This step will help improve the industry and strengthen the reputation of VAPE and HIVE Holdings.
A few of company’s newly designed product will be offered on the HIVE website in the upcoming period. Along with the strengthening of foundation, they intend to selectively distribute premium products from other brands as and when the opportunities come. This will help customers to do more of purchasing from them.
Many of company’s recent problems have been a result of the investments that haven’t yielded earnings surpassing the cost of capital. As a result, Vape Holdings have been working diligently to close the debt consolidation and stabilize their capital structure. The company also intends to work with investors to handle the conversion of notes outstanding so that the impact of new shares is manageable.
Vape management reported that they are committed to providing information about their development on these matters. They are working to revitalize company as they receive offers and advice from shareholders within the market to help where ever they can. The management appreciates this tremendously and anticipates coordinating with all parties to get a positive result. They would be pleased if any of the shareholders contacts Investor Relations team to get updates or know about potential joint efforts.
OXIS International, Inc. (OTCMKTS:OXIS): Bears in Control
OXIS International, Inc. (OTCMKTS:OXIS) is edging lower in the market, investors having shrugged off a series of positive news on the clinical trial front. The stock is currently trading at the lower end of its tight range of $0.17- $0.20 a share. Given the rate at which the bears are pushing the stock lower in the market, it appears the stock could crash to its 52-week low of $0.15 a share.
The change in investor sentiments on the stock comes even on Oxis reiterating positive results from its ongoing clinical trials. The company has already received the FDA approval for a Phase II trial of its lead candidate drug OXS-1550 that targets leukemia. The drug has already demonstrated success in early human clinical trials and there is hope that it could act as a powerful alternative to chemotherapy.
OXIS International, Inc.(OTCMKTS:OXIS) is also working on OXS-4235 a novel treatment for Multiple Myeloma as well as OXS-2175 that targets breast cancer.
